LillyDirect Review: Zepbound Self-Pay, and the Year With Thirteen Months

Self-pay, per fill, by dose: $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg, 10 mg, 12.5 mg and 15 mg — that last figure only if you refill within 45 days. Miss that window and Lilly's own footnote applies: $499 at 7.5 mg and $699 at 10 mg and above. The single-dose vial and the single-patient-use KwikPen cost exactly the same at every dose. There’s no membership, no consultation charge and no subscription. Read off lilly.com/lillydirect/medicines/zepbound on August 7, 2026.

Because Lilly doesn’t sell you a month. Under its own price list, in the terms marked with an asterisk: "Month is defined as 28-days and 1 single-patient-use KwikPen" — and, for the vial, "28-days and 4 single-dose vials". Twenty-eight days is four weeks, and there are thirteen four-week periods in a year, which is why the Zepbound savings terms cap participation at "a maximum of up to 13 prescription fills per calendar year." So a year at $449 is $5,837, not $5,388. At the late-refill price of $699 it’s $9,087. Any comparison that multiplies these prices by twelve is understating them by a full month.

It’s the condition attached to the maintenance-dose price, and it’s expensive to break. At 7.5 mg and above, $449 is described as the price "when you refill within 45 days" under the Zepbound Journey Program. The footnote states the alternative in full: $499 at 7.5 mg, and $699 at 10 mg, 12.5 mg and 15 mg. On a 10 mg prescription that’s $250 extra for the same pen, triggered by nothing more than a late reorder. If you’re traveling, changing doctors or waiting on a lab, the clock is the thing to watch.

At maintenance doses, increasingly yes. A telehealth service that resells Lilly's own product has to charge Lilly's price plus its own margin — which is why Ro's Zepbound bill is $598 a month, being a $149 membership on top of $449 of medication that came from here. Buying direct removes the membership. What it also removes is the prescriber: LillyDirect fills prescriptions, it doesn’t write them, so you need a doctor of your own or one of the independent telehealth providers Lilly links to, and several of those charge for the visit. The arithmetic favors going direct if you already have a prescriber.

Two things, both worth knowing before you enroll. First, reimbursement: Lilly's self-pay fulfillment partner Gifthealth requires that "you agree not to seek payment or accept reimbursement, either directly or indirectly, from any insurance plan or other third-party payer." Cash spent here doesn’t count toward a deductible or an out-of-pocket maximum. Second, eligibility: governmental beneficiaries are excluded, which Lilly defines as "any state, federal, or government funded healthcare program, like Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state prescription drug assistance program."

No, and that’s unusual enough to say plainly. The self-pay ladder is identical for both: $299, $399 and $449 by dose, with the same 45-day condition at 7.5 mg and above. The differences are practical. The vial is self-pay only and sold exclusively through LillyDirect, and it needs a needle and syringe you buy separately, drawn up by hand. The KwikPen is a multi-dose pen that also accepts insurance, and it needs pen needles you buy separately. Neither device includes what you need to inject it.

Real, and not a cash price. That figure applies to the Zepbound Single-Dose Pen for patients with commercial insurance that already covers Zepbound — it’s a copay reduction, capped at $150 of savings a month and $1,300 a calendar year, and government beneficiaries are excluded. There’s a third schedule too: commercially insured patients whose plan doesn’t cover Zepbound can pay $299 to $449 on a savings card. Three price schedules sit on the same Lilly page, and only one of them — the self-pay ladder — is what an uninsured cash buyer pays. This review prices that one and nothing else.

Both are on LillyDirect, and Foundayo is the one to watch on price. Lilly's own directory advertises Foundayo (orforglipron), its oral GLP-1, as "Starting at $149 through LillyDirect self pay" — less than half the entry price of Zepbound, and a tablet rather than an injection. We haven’t priced it as a row here because Lilly publishes a single starting figure rather than a dose ladder, and a "starting at" with no maintenance price behind it’s exactly the kind of number this site refuses to treat as a monthly cost. Ask what the 12 mg and 36 mg doses cost before you assume $149 is your year.